The CHRYSALIS Study is evaluating the safety and effectiveness of an investigational medication for different groups of people with NSCLC. Participants in the groups that are currently enrolling need to have NSCLC with either a primary gene mutation known as the MET Exon 14 skipping mutation or NSCLC with types known as adenocarcinoma or squamous cell carcinoma without certain gene mutations (EGFR and ALK) on tumor testing. Learn more about the CHRYSALIS research study here.
The CHRYSALIS 2 Study is evaluating the safety and effectiveness of an investigational medication in combination with another investigational medication for different groups of people with advanced NSCLC. Learn more about the Chrysalis 2 research study here.
The MARIPOSA Study is evaluating the safety and effectiveness of one investigational medication or a combination of two investigational medications. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution.
The MARIPOSA 2 Study is evaluating the safety and effectiveness of a combination of two investigational medications in addition to approved chemotherapy. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution. Learn more about the MARIPOSA 2 research study here.
The PAPILLON Study is evaluating the safety and effectiveness of an investigational medication in combination with chemotherapy. Participants in this study need to have a rare form of EGFR mutation called an Exon 20 insertion. Learn more about the PAPILLON research study here.
If you are not sure which research study is for you, take this short survey to find out.
If you want to learn how biomarker testing can determine mutation types, visit this page.
This website includes information about clinical research studies in the United States. To see a list of participating countries please visit this page.
Below is a list of currently participating countries for the Chrysalis, Chrysalis 2, Mariposa, Mariposa 2, and Papillon clinical research studies. For more information, please visit ClinicalTrials.gov.
Participating Country
north america
Canada
Puerto Rico
United States
Europe
Belgium
Bulgaria
Czech Republic
Denmark
France
Germany
Hungary
Italy
Netherlands
Poland
Portugal
Russia
Spain
Sweden
Turkey
Ukraine
United Kingdom
Asia & Pacific
Australia
China
Hong Kong
India
Japan
Korea
Malaysia
Taiwan
Thailand
South / Latin America
Argentina
Brazil
Mexico
Middle East
Israel
The more we learn, the farther we can go.